About us Contacts Drug interactions: 390 212
Drug search by name

Carbamazepine Extended-Release Capsules (Carbatrol) and Trabectedin

Determining the interaction of Carbamazepine Extended-Release Capsules (Carbatrol) and Trabectedin and the possibility of their joint administration.

Check result:
Carbamazepine Extended-Release Capsules (Carbatrol) <> Trabectedin
Relevance: 10.10.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

CarBAMazepine may reduce the blood levels of trabectedin, which may make the medication less effective in treating your cancer. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. In 9 study patients with advanced malignancies, administration of a single 1.3 mg/m2 infusion of trabectedin on day 6 of treatment with rifampin (600 mg daily for 6 days), a potent CYP450 3A4 inducer, resulted in a 22% decrease in mean trabectedin peak plasma concentration (Cmax) and 31% decrease in mean systemic exposure (AUC) compared to infusion of trabectedin alone. Most trabectedin-related toxicities including nausea, thrombocytopenia, neutropenia, leukopenia, and liver function abnormalities occurred at a higher frequency with trabectedin alone compared to trabectedin coadministered with rifampin. Grade 3 and 4 adverse events were also observed more often with trabectedin alone. Only vomiting and fatigue were reported more often during coadministration of trabectedin with rifampin.

MANAGEMENT: Given the potential for diminished pharmacologic effects of trabectedin in the presence of potent CYP450 3A4 inducers, concomitant use should generally be avoided.

References
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • Machiels JP, Staddon A, Herremans C, et al. "Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies." Cancer Chemother Pharmacol 74 (2014): 729-37
  • "Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals, Titusville, NJ.
Carbamazepine Extended-Release Capsules (Carbatrol)

Generic Name: carbamazepine

Brand name: Carbatrol, Epitol, Equetro, Tegretol, Tegretol XR, Tegretol, Tegretol XR

Synonyms: Carbamazepine, CarBAMazepine

Trabectedin

Generic Name: trabectedin

Brand name: Yondelis

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.